DRMAHIGH SIGNALOPPORTUNITY10-K

DRMA achieved statistically significant results in its Phase 3 STAR-1 clinical trial for XYNGARI in March 2025, while simultaneously strengthening its balance sheet with dramatically improved cash position and reduced liabilities.

The successful Phase 3 trial represents a major inflection point for this skincare-focused biotech, potentially positioning XYNGARI for FDA approval and commercialization in the moderate-to-severe acne market. The company appears to have successfully raised capital during this period, evidenced by the massive increase in current assets and cash position, providing runway to advance their lead asset through regulatory processes.

Comparing 2026-03-26 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

DRMA's financial position improved dramatically across all key metrics, with current assets surging nearly 20x to $11.6M and cash more than doubling to $7.5M, while current liabilities were cut in half to $1.5M. R&D expenses declined 64% to $2.9M and net losses narrowed significantly from -$12.3M to -$7.6M, suggesting more disciplined capital allocation following the successful Phase 3 trial results. The overall financial picture signals a well-capitalized company that has likely completed a significant financing round and is managing cash burn more effectively while advancing its lead clinical program.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+1819.9%
$605K→$11.6M

Current assets grew 1819.9% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+298.7%
$1.6M→$6.2M

Equity base grew 298.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+137.9%
$3.2M→$7.5M

Cash position surged 137.9% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
+122.5%
$3.5M→$7.9M

Asset base grew 122.5% — expansion through organic growth, acquisitions, or capital deployment.

Interest Expense
P&L
-76.9%
$197K→$46K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

R&D Expense
P&L
-64.3%
$8.2M→$2.9M

R&D spending cut 64.3% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
-59.9%
$3.8M→$1.5M

Current liabilities reduced — improved short-term financial position and working capital health.

Net Income
P&L
+38.5%
-$12.3M→-$7.6M

Net income grew 38.5% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+37.9%
-$12.5M→-$7.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+30.5%
-$11.2M→-$7.8M

Operating cash flow surged 30.5% — exceptional cash generation, highest quality earnings signal.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-17
ADDED
As of March 25, 2026, the number of outstanding shares of the registrant s common stock, par value $ 0.0001 per share, was 4,022,143 .
However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.
Overview We are a scientific leader in skincare, dedicated to the development and commercialization of products that address common and underserved skin conditions.
Dermata initially was founded with a focus on researching and developing prescription products subject to the FDA approval process.
As part of this focus, we had one lead asset, referred to as XYNGARI, also known as DMT310, which we had been studying in clinical trials for the treatment of moderate-to-severe acne.
+7 more — sign up free →
REMOVED
drma_10k.htm 0001853816 false --12-31 FY 2024 false 0.0001 250000000 2517768 261998 1526232 false false false false Cybersecurity Risk Management and Strategy In the ordinary course of our business, we may use, store and process confidential information and data.
To effectively prevent, detect, and respond to cybersecurity threats, we maintain a cyber risk management program, which is comprised of data segregation, physical, procedural, and technical safeguards along with some documented policies and procedures.
By fully outsourcing our IT environment and placing it within expert third party software-as-a-service, human resource, and clinical providers, our primary means of minimizing cybersecurity risk is limiting the amount of sensitive data within our enterprise.
We have certain processes for assessing, identifying, and managing cybersecurity risks, which are built into our overall information technology function and are designed to help protect our information assets and operations from internal and external cyber threats, and protect employee, collaborator, and patient information from unauthorized access or attack, as well as secure our networks and systems.
Such processes include physical, procedural, and technical safeguards, response plans, tests on our systems, review of our policies and procedures to identify risks and refine our practices.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →